AOD-9604

Also known as: Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191

Weight LossPHASE 2

Clinical Status

Clinical trials completed — did not achieve FDA approval for obesity.

Mechanism of Action

Mimics the lipolytic effects of growth hormone without affecting blood sugar or tissue growth. Stimulates lipolysis and inhibits lipogenesis.

Dosing Defaults

Dose

300 mcg

Frequency

1x daily

Administration

Subcutaneous injection

Timing

Morning (fasted)

Food

fasted

Duration

12-24 weeks

Dose range: 250-500 mcg daily

Morning fasted dosing optimizes fat metabolism effects.

Side Effects

•Injection site reactions
•Mild headache
•Dizziness

Contraindications & Warnings

•Not medical advice

Compare

Compare AOD-9604 with another peptide side-by-side.

Calculate Dose

Use the reconstitution calculator to prepare your AOD-9604 dose.

Open Calculator

Related Weight Loss Peptides

Semaglutide

FDA APPROVED

Weight Loss

GLP-1 receptor agonist. FDA-approved for type 2 diabetes and weight management.

Tirzepatide

FDA APPROVED

Weight Loss

Dual GLP-1/GIP receptor agonist. FDA-approved for T2D and weight management.

Retatrutide

PHASE 3

Weight Loss

Triple receptor agonist (GLP-1/GIP/Glucagon). Most potent weight loss peptide in trials.

Liraglutide

FDA APPROVED

Weight Loss

Daily GLP-1 agonist. FDA-approved for both diabetes and weight management.

This information is for educational purposes only and is not medical advice. Dosing data is based on research literature and community reports. Always consult a qualified healthcare provider before using any peptide.